New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 26, 2014
09:20 EDTICPTLeerink cautious on Intercept ahead of FLINT data
Leerink initiated shares of Intercept with a Market Perform rating saying it is cautious ahead of the full FLINT data. The firmís talks with a specialist indicated that robust improvements in fibrosis are required to offset concerns about plasma lipids and excess cardiovascular events. Leerink set a $270 price target for the stock. Shares of Intercept were also initiated this morning at Nomura with a Neutral rating.
News For ICPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 4, 2015
16:34 EDTICPTShareholder suit against Intercept allowed to proceed, Reuters reports
Subscribe for More Information
15:52 EDTICPTShareholder suit against Intercept allowed to proceed, Reuters reports
11:09 EDTICPTSanofi, Novartis, Shire may be weighing Genfit acquisition, Bloomberg says
Subscribe for More Information
March 3, 2015
07:35 EDTICPTIntercept risk/reward positive, says RBC Capital
RBC Capital believes that Intercept will rally 20% or more if GenFit data, expected to be announced in the second half of March, isn't clean. If the GenFit data is positive, Intercept's stock might drop, but it would probably rebound, since the company would probably reach a deal with the FDA on a Phase III trial of its OCA drug soon thereafter, according to the firm. RBC keeps a $490 price target and Outperform rating on Intercept.
March 2, 2015
06:13 EDTICPTIntercept reports Q4 EPS ($1.63), consensus ($1.67)
Subscribe for More Information
February 19, 2015
16:31 EDTICPTIntercept promotes Lisa Bright to Chief Commercial & Corporate Affairs Officer
Intercept Pharmaceuticals announced that Lisa Bright has been promoted to the newly-created position of Chief Commercial and Corporate Affairs Officer. Bright joined Intercept last year from Gilead Sciences where her leadership of the European launch of Sovaldi for the treatment of chronic hepatitis C contributed to the most successful product launch in pharmaceutical history.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use